Corcept Therapeutics to Announce Second Quarter 2016 Financial Results and Corporate Update and Host Conference Call
July 26, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jul 26, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Corcept Therapeutics Appoints Renee D. Gala to Board of Directors
June 28, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jun 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that...
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
June 02, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
Preliminary efficacy results in Phase 1/2 trial of mifepristone plus...
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
May 03, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - May 3, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
First quarter revenue of $16.1 million, a 59 percent increase from the...
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
April 29, 2016 08:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Apr 29, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May...
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers
April 28, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Apr 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs...
Corcept Therapeutics Announces 2015 Financial Results
March 01, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Mar 1, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
Full year 2015 revenue of $50.3 million, an 89 percent increase from...
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial Results, Provides 2016 Revenue Guidance and Corporate Update
January 28, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jan 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
Full year 2015 revenue of $50.3 million, an 89 percent increase from...
Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call
January 21, 2016 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jan 21, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2015 financial results and...
Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer
December 14, 2015 08:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Dec 14, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that...